Edwards Lifesciences Corp (EW) Factsheet
Edwards Lifesciences Corp (EW) Stock Analysis
Analysis from 10-Q filed 2025-11-05. Data as of Q4 2025.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 9.7%. FCF margin 22.0%. D/E 0.1x. Source: 10-Q filed 2025-11-05.
| Metric | Value | Context |
|---|---|---|
| ROIC | 9.7% | Near cost of capital |
| FCF Margin | 22.0% | Strong cash generation |
| Debt/Equity | 0.1x | Conservative leverage |
ROIC 9.7% — Top 50% of sector peers. FCF margin 22.0% — Top 5%.
Explore Edwards Lifesciences Corp: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for EW: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Edwards Lifesciences Corp earns 9.7% ROIC, Top 50% in Healthcare
ROIC TTM 9.7%, sector median -2.5%, Top 50%. DuPont: NOPAT margin 17.3% × asset turnover 0.5x. Gross margin 78.0%. Operating margin 20.8%. Source: 10-Q filed 2025-11-05.
| Metric | EW | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Adequate | Above sector median of -2.5% |
| Return on Equity (ROE) | 10.5% | Adequate | Moderate equity returns |
| Gross Margin | 78.0% | Excellent | Strong pricing power |
| Operating Margin | 20.8% | Excellent | Efficient operations |
Cash Flow: Edwards Lifesciences Corp generates $1.3B FCF at 22.0% margin, positive NaN/8 quarters
FCF TTM $1.3B. FCF margin 22.0%, Top 5%. OCF/Net income 1.5x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-05.
| Metric | EW | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 22.0% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $1.3B | Good | Positive cash generation |
| OCF/Net Income | 1.5x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Edwards Lifesciences Corp at 0.1x leverage
Debt/Equity 0.1x. Net cash $3.6B. Source: 10-Q filed 2025-11-05.
| Metric | EW | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.1x | Excellent | Conservative capital structure |
| Net Cash Position | $3.6B | Excellent | Net cash positive |
Valuation: Edwards Lifesciences Corp trades at 46.4x earnings
P/E 46.4x. EV/Sales 7.7x. FCF yield 2.7%. Source: 10-Q filed 2025-11-05.
| Metric | EW | Rating | Context |
|---|---|---|---|
| P/E Ratio | 46.4x | Adequate | Premium valuation |
| EV/Sales | 7.7x | Adequate | Growth premium priced in |
| FCF Yield | 2.7% | Adequate | Lower cash yield |
Capital Allocation: Edwards Lifesciences Corp returns 1.8% shareholder yield
Total shareholder yield 1.8% (buyback 1.8%). Capital returned $893.4M TTM. Source: 10-Q filed 2025-11-05.
| Metric | EW | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 1.8% | Adequate | Dividend + buyback yield combined |
| Buyback Yield | 1.8% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $893.4M | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Top 50% | - |
| Free Cash Flow Margin | 22.0% | Top 5% | - |
| Gross Margin | 78.0% | Top 50% | 1.2x above |
| Operating Margin | 20.8% | Top 25% | 9.1x above |
| Return on Equity (ROE) | 10.5% | Top 50% | - |
| P/E Ratio | 46.4x | N/A | - |
Financial Scorecard
| Metric | EW | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Adequate | Top 50% of sector (median: -2.5%) |
| Free Cash Flow Margin | 22.0% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 78.0% | Excellent | Top 50% of sector (median: 64.7%) |
| Debt to Equity Ratio | 5.8% | Excellent | Conservative capital structure |
| P/E Ratio (Price-to-Earnings) | 46.4x | Adequate | High expectations priced in |
| Free Cash Flow Yield | 2.7% | Warning | Growth-focused valuation |
Frequently Asked Questions
Q: What is Edwards Lifesciences Corp's Return on Invested Capital (ROIC)?
Edwards Lifesciences Corp (EW) has a trailing twelve-month Return on Invested Capital (ROIC) of 9.7%. Sector median -2.5%. Source: 10-Q filed 2025-11-05.
Q: What is Edwards Lifesciences Corp's Free Cash Flow Margin?
Edwards Lifesciences Corp (EW) has a free cash flow margin of 22.0%, generating $1.3 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-05.
Q: What is Edwards Lifesciences Corp's P/E ratio and how does it compare to peers?
Edwards Lifesciences Corp (EW) trades at a P/E ratio of 46.4x, which is above the sector median of N/A. EV/Sales 7.7x. FCF yield 2.7%. Source: 10-Q filed 2025-11-05.
Q: What is Edwards Lifesciences Corp's revenue and earnings growth?
Edwards Lifesciences Corp (EW) grew revenue by 11.5% year-over-year. EPS -73.7% YoY. Source: 10-Q filed 2025-11-05.
Q: Is Edwards Lifesciences Corp buying back stock?
Edwards Lifesciences Corp (EW) repurchased $893.4 million of stock over the trailing twelve months. This represents a buyback yield of 1.8%. Source: 10-Q filed 2025-11-05.
Q: How does Edwards Lifesciences Corp compare to competitors in Healthcare?
Compared to other companies in Healthcare, Edwards Lifesciences Corp (EW) shows: ROIC 9.7%, sector median -2.5% (Top 50%). FCF margin 22.0%, sector median 0.0% (Top 5%). Gross margin 78.0%, 13.3pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Edwards Lifesciences Corp?
Quantitative warning flags for Edwards Lifesciences Corp (EW): 1) ROIC declining -10.8% over 8 quarters. Source: 10-Q filed 2025-11-05.
Data Source: Data sourced from 10-Q filed 2025-11-05. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.